Research brief · 2026-09-09
Why 'It Worked in Mice' Usually Means Nothing
A striking animal result is where a lot of health claims begin, and BPC-157 shows why that is a starting line, not a finish. In 2003, Staresinic and colleagues published a study in the Journal of Orthopaedic Research in which the Achilles tendon of rats was surgically cut and the animals were then treated with BPC-157. Compared with untreated controls, whose healing was severely compromised, the treated tendons showed higher load-to-failure, better elasticity, more organised collagen, and by day fourteen the re-establishment of full tendon integrity.
That finding is not alone. A PubMed search for BPC-157 tendon healing in rats returns around nineteen results, most showing consistent, favourable outcomes in rodent injury models. BPC-157 is not approved for human use, and this animal literature is essentially the whole evidence base.
The human record is different. ClinicalTrials.gov lists one verifiable human trial, NCT02637284, a 2015 Phase 1 pilot in forty-two healthy volunteers. It tested only the safety and pharmacokinetics of an oral tablet, and it never posted results. It was built to ask whether the compound was safe to swallow, not whether it heals anything. No completed human trial has tested tendon healing.
Why does the gap matter? Rodent models are useful for hypotheses and mechanism, but healing timelines, immune responses, tendon blood supply and injury mechanics all differ between species. Many compounds with strong animal results show much smaller effects, or none, when tested in people. That is why regulators require dedicated human trials no matter how consistent the preclinical data looks.
The honest limit is that the human question has not been tested in either direction. Two decades of positive rat studies and zero human tendon trials is the record. A plausible mechanism makes a result easier to believe; it is not evidence of an effect in a different species.
Sources
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
- Journal of Orthopaedic Research 2003
- ClinicalTrials.gov. NCT02637284, Phase I pilot study of PCO-02 (BPC-157) in healthy volunteers
- ClinicalTrials.gov 2015
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.